-
DailyClout Makes Legislation Easy to Understand, Share and Act Upon
Join the CommunitySearch BillCam
-
LET'S SAVEDEMOCRACYTOGETHER
July 6, 2021
DailyClout
“FIVE FREEDOMS” – CITIZENS’ CORNER: Open Letter from Physicians to Universities: Allow Students Back Without COVID Vaccine Mandate
READ Paul M. Kempen’s, M.D., Ph.D. – AAPS President (2021), letter in AAPS (Association of American Physicians and Surgeons).
July 5, 2021
DailyClout
“FIVE FREEDOMS” – BULLETIN BOARD: Elk Grove CA Campaigns Against Telecoms Stripping Local Communities of Rights
July 5, 2021 Dear reader, It is crunch time in the Legislature. Telecom bills are in their final committees and this is one of our last chances to stop them. This newsletter gives you instructions on how to call and email the Committee members to oppose these bills. Please …
July 5, 2021
DailyClout
“FIVE FREEDOMS” – NEWS FEED: VAERS COVID-19 Vaccine Adverse Events Data
The Vaccine Adverse Events Reporting System (VAERS) was established in 1990 as a national early warning system to detect possible safety problems in U.S.-licensed vaccines. It is a passive system so reporting is voluntary and this leads to significant undercounting of harms. Harvard Pilgrim Health Care, Inc. conducted a …
July 5, 2021
DailyClout
“FIVE FREEDOMS” – BULLETIN BOARD: OpenVAERS Call to Action on Social Media Censorship
The censorship on social media is completely out of control. The Facebook algorithm now searches images for the words VAERs, OpenVAERS, and/or vaccine and will instantly apply up to 3 warning labels to any post that includes content from this site. Remember these are government reports on a government …
July 5, 2021
DailyClout
“FIVE FREEDOMS” – NEWS FEED: With BioNTech Deal, Pfizer Becomes Latest to Bet on mRNA Vaccines
Pfizer has become the latest drug maker to bet that synthetic messenger RNA molecules (mRNA) can be a new source for vaccines. This morning, the New York pharma company cut a deal with BioNTech, of Germany, to co-develop mRNA vaccines for flu prevention. READ Ben Fidler’s article in Xconomy